ARROWHEAD PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
(c)Trading Plans
During the quarter ended March 31, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
| Name | Title | Adoption Date | Plan Start Date | Plan End Date | SharesVesting andSubject toSell-To-Cover (1) | OtherSharesBeing Sold(Subject toCertainConditions) |
|---|---|---|---|---|---|---|
| James Hamilton | Chief Discovery and Translational Medicine | 3/26/2024 | 1/6/2025 | 1/17/2025 | 60,000 | n/a |
| Ken Myszkowski | Chief Financial Officer | 3/12/2024 | 6/11/2024 | 2/28/2025 | n/a | 115,000 |
| Ken Myszkowski | Chief Financial Officer | 3/28/2024 | 1/6/2025 | 1/17/2025 | 15,000 | n/a |
| Ken Myszkowski | Chief Financial Officer | 3/28/2024 | 1/6/2025 | 1/17/2025 | 15,000 | n/a |
| Ken Myszkowski | Chief Financial Officer | 3/28/2024 | 1/6/2025 | 1/17/2025 | 15,000 | n/a |
| Ken Myszkowski | Chief Financial Officer | 3/28/2024 | 1/6/2025 | 1/17/2025 | 18,750 | n/a |
| Patrick O'Brien | Chief Operating Officer and General Counsel | 3/21/2024 | 1/6/2025 | 1/17/2025 | 67,500 | n/a |
| William Waddill | Board Member | 3/27/2024 | 12/16/2024 | 12/31/2024 | n/a | 7,495 |
(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.